These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterisation of CMY-4, an AmpC-type plasmid-mediated beta-lactamase in a Tunisian clinical isolate of Proteus mirabilis. Verdet C; Arlet G; Ben Redjeb S; Ben Hassen A; Lagrange PH; Philippon A FEMS Microbiol Lett; 1998 Dec; 169(2):235-40. PubMed ID: 9868767 [TBL] [Abstract][Full Text] [Related]
3. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli. Mirelis B; Rivera A; Miró E; Mesa RJ; Navarro F; Coll P Enferm Infecc Microbiol Clin; 2006; 24(6):370-2. PubMed ID: 16792938 [TBL] [Abstract][Full Text] [Related]
4. CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. D'Andrea MM; Nucleo E; Luzzaro F; Giani T; Migliavacca R; Vailati F; Kroumova V; Pagani L; Rossolini GM Antimicrob Agents Chemother; 2006 Feb; 50(2):618-24. PubMed ID: 16436718 [TBL] [Abstract][Full Text] [Related]
5. Emergence of a cefepime- and cefpirome-resistant Citrobacter freundii clinical isolate harbouring a novel chromosomally encoded AmpC beta-lactamase, CMY-37. Ahmed AM; Shimamoto T Int J Antimicrob Agents; 2008 Sep; 32(3):256-61. PubMed ID: 18619820 [TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics]. Susić E Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687 [TBL] [Abstract][Full Text] [Related]
7. Four variants of the Citrobacter freundii AmpC-Type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. Literacka E; Empel J; Baraniak A; Sadowy E; Hryniewicz W; Gniadkowski M Antimicrob Agents Chemother; 2004 Nov; 48(11):4136-43. PubMed ID: 15504832 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL; BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738 [TBL] [Abstract][Full Text] [Related]
9. Phenotypic and molecular characterization of plasmid mediated AmpC β-lactamases among Escherichia coli, Klebsiella spp., and Proteus mirabilis isolated from urinary tract infections in Egyptian hospitals. Helmy MM; Wasfi R Biomed Res Int; 2014; 2014():171548. PubMed ID: 25003107 [TBL] [Abstract][Full Text] [Related]
10. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia. Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339 [TBL] [Abstract][Full Text] [Related]
12. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF]. Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100 [TBL] [Abstract][Full Text] [Related]
13. Characterization and nucleotide sequence of a Klebsiella oxytoca cryptic plasmid encoding a CMY-type beta-lactamase: confirmation that the plasmid-mediated cephamycinase originated from the Citrobacter freundii AmpC beta-lactamase. Wu SW; Dornbusch K; Kronvall G; Norgren M Antimicrob Agents Chemother; 1999 Jun; 43(6):1350-7. PubMed ID: 10348751 [TBL] [Abstract][Full Text] [Related]
14. Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. Féria C; Ferreira E; Correia JD; Gonçalves J; Caniça M J Antimicrob Chemother; 2002 Jan; 49(1):77-85. PubMed ID: 11751770 [TBL] [Abstract][Full Text] [Related]
15. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Tan TY; Ng SY; Teo L; Koh Y; Teok CH J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079 [TBL] [Abstract][Full Text] [Related]
16. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635 [TBL] [Abstract][Full Text] [Related]
17. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings. Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292 [TBL] [Abstract][Full Text] [Related]
18. Characterization of Beta-lactamases in Faecal Enterobacteriaceae Recovered from Healthy Humans in Spain: Focusing on AmpC Polymorphisms. Porres-Osante N; Sáenz Y; Somalo S; Torres C Microb Ecol; 2015 Jul; 70(1):132-40. PubMed ID: 25501887 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital. Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475 [TBL] [Abstract][Full Text] [Related]
20. beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Pitout JD; Thomson KS; Hanson ND; Ehrhardt AF; Moland ES; Sanders CC Antimicrob Agents Chemother; 1998 Jun; 42(6):1350-4. PubMed ID: 9624474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]